{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:23:23Z","timestamp":1788319403760,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008238","name":"Hebei Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["21377798D"],"award-info":[{"award-number":["21377798D"]}],"id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clinthera.2025.06.017","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:16:09Z","timestamp":1753355769000},"page":"729-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Vunakizumab Treatment on Detailed Dimensions of Patient-Reported Outcomes in Moderate-to-Severe Plaque Psoriasis Patients: A Post-Hoc Analysis of a Randomized Controlled Trial (NCT04839016)"],"prefix":"10.1016","volume":"47","author":[{"given":"Lijing","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10281","key":"10.1016\/j.clinthera.2025.06.017_bib0001","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.clinthera.2025.06.017_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.clinthera.2025.06.017_bib0003","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.clinthera.2025.06.017_bib0004","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000528945","article-title":"Patient perspectives on psoriatic disease burden: results from the Global Psoriasis and Beyond survey","volume":"239","author":"Armstrong","year":"2023","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.clinthera.2025.06.017_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ad.2022.07.021","article-title":"Quality of life and body region affected by psoriasis: a systematic review","volume":"114","author":"Nabieva","year":"2023","journal-title":"Actas Dermosifiliogr"},{"issue":"11","key":"10.1016\/j.clinthera.2025.06.017_bib0006","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-024-02110-8","article-title":"Vunakizumab: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.clinthera.2025.06.017_bib0007","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2024.09.031","article-title":"Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"92","author":"Yan","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.clinthera.2025.06.017_bib0008","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/bjd.13691","article-title":"Patient-reported outcome measures in psoriasis: the good, the bad and the missing!","volume":"172","author":"Kitchen","year":"2015","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.clinthera.2025.06.017_bib0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/14737167.2014.914437","article-title":"Quality of life in psoriasis patients","volume":"14","author":"Augustin","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.clinthera.2025.06.017_bib0010","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1365-2133.2011.10469.x","article-title":"Patient-reported outcomes in psoriasis research and practice","volume":"165","author":"Otuki","year":"2011","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.clinthera.2025.06.017_bib0011","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jamadermatol.2023.5439","article-title":"Patient-reported outcome measures for health-related quality of life in patients with psoriasis: a systematic review","volume":"160","author":"Perez-Chada","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.clinthera.2025.06.017_bib0012","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"10.1016\/j.clinthera.2025.06.017_bib0013","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"19","key":"10.1016\/j.clinthera.2025.06.017_bib0014","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.2106\/JBJS.O.00030","article-title":"Scoring the SF-36 in orthopaedics: a brief guide","volume":"97","author":"Laucis","year":"2015","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"10.1016\/j.clinthera.2025.06.017_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clinthera.2025.06.017_bib0016","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.det.2024.02.001","article-title":"Biologics for psoriasis","volume":"42","author":"Wride","year":"2024","journal-title":"Dermatol Clin"},{"issue":"3","key":"10.1016\/j.clinthera.2025.06.017_bib0017","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1080\/09546634.2020.1853023","article-title":"Disease response and patient-reported outcomes among initiators of ixekizumab","volume":"33","author":"Shahriari","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.clinthera.2025.06.017_bib0018","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40257-019-00466-2","article-title":"Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with Brodalumab for 5 years in a long-term, open-label, phase II study","volume":"20","author":"Lebwohl","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.clinthera.2025.06.017_bib0019","doi-asserted-by":"crossref","first-page":"394","DOI":"10.36849\/JDD.5821","article-title":"Effect of Ixekizumab on patient reported outcomes and quality of life in patients with moderate-to-severe plaque psoriasis: 5-year results from the UNCOVER-1 and -2 studies","volume":"20","author":"Gooderham","year":"2021","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"10.1016\/j.clinthera.2025.06.017_bib0020","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/09546634.2017.1329501","article-title":"Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population","volume":"28","author":"Norris","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.clinthera.2025.06.017_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2200872","article-title":"Quality of life and patient-reported symptoms in a phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: week 28 interim analysis","volume":"34","author":"Bhatia","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.clinthera.2025.06.017_bib0022","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/jdv.18820","article-title":"Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study","volume":"37","author":"Navarini","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2025.06.017_bib0023","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.genhosppsych.2022.01.006","article-title":"Associations between psoriasis and mental illness: an update for clinicians","volume":"75","author":"Hedemann","year":"2022","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.clinthera.2025.06.017_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880201","article-title":"Epidemiology of Psoriasis and comorbid diseases: a narrative review","volume":"13","author":"Bu","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clinthera.2025.06.017_bib0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/ijd.ijd_241_22","article-title":"The effects of methotrexate and biologics on the symptoms of depression and anxiety in patients with psoriasis","volume":"68","author":"Ugurer","year":"2023","journal-title":"Indian J Dermatol"},{"issue":"5","key":"10.1016\/j.clinthera.2025.06.017_bib0026","first-page":"13","article-title":"Biologic therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients","author":"Timis","year":"2023","journal-title":"Life (Basel)"},{"issue":"3","key":"10.1016\/j.clinthera.2025.06.017_bib0027","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3712","article-title":"Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study","volume":"101","author":"Talamonti","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"(19","key":"10.1016\/j.clinthera.2025.06.017_bib0028","article-title":"Pathomechanism of pruritus in psoriasis and atopic dermatitis: novel approaches, similarities and differences","volume":"24","author":"Kaczmarska","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.clinthera.2025.06.017_bib0029","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/09546634.2018.1528330","article-title":"Psoriasis-associated cutaneous pain: etiology, assessment, impact, and management","volume":"30","author":"Pithadia","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.clinthera.2025.06.017_bib0030","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s13555-024-01147-7","article-title":"Sustained improvements in clinical and patient-reported outcomes and quality of life through 5 years among Ixekizumab-treated patients with complete clearance of scalp psoriasis by week 60","volume":"14","author":"Egeberg","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"10.1016\/j.clinthera.2025.06.017_bib0031","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jaad.2016.07.034","article-title":"Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials","volume":"75","author":"Kimball","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.clinthera.2025.06.017_bib0032","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jdv.14913","article-title":"Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials","volume":"32","author":"Gottlieb","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.clinthera.2025.06.017_bib0033","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1080\/09546634.2022.2116266","article-title":"Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting","volume":"33","author":"Strober","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clinthera.2025.06.017_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2014.03.004","article-title":"Participation of interleukin 17A in neuroimmune interactions","volume":"41","author":"Moynes","year":"2014","journal-title":"Brain, behavior, and immunity"},{"issue":"21","key":"10.1016\/j.clinthera.2025.06.017_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218406","article-title":"Molecular and cellular mechanisms of itch in psoriasis","volume":"21","author":"Komiya","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.clinthera.2025.06.017_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002939","article-title":"Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study","volume":"9","author":"Coates","year":"2023","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.clinthera.2025.06.017_bib0037","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/bjd.13647","article-title":"Fatigue in psoriasis: a phenomenon to be explored","volume":"172","author":"Skoie","year":"2015","journal-title":"Br J Dermatol"},{"issue":"22","key":"10.1016\/j.clinthera.2025.06.017_bib0038","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"10.1016\/j.clinthera.2025.06.017_bib0039","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/JD9.0000000000000244","article-title":"Efficacy and safety of Ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study","volume":"5","author":"Li","year":"2022","journal-title":"Int J Dermatol Venereol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:01:55Z","timestamp":1763787715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0149291825002346"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Vunakizumab Treatment on Detailed Dimensions of Patient-Reported Outcomes in Moderate-to-Severe Plaque Psoriasis Patients: A Post-Hoc Analysis of a Randomized Controlled Trial (NCT04839016)","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}